Aspire Biopharma Holdings (ASBP) Total Current Liabilities (2021 - 2026)

Aspire Biopharma Holdings (ASBP) has 6 years of Total Current Liabilities data on file, last reported at $3.2 million in Q1 2026.

• On a quarterly basis, Total Current Liabilities fell 68.06% year-over-year to $3.2 million in Q1 2026; TTM through Mar 2026 was $3.2 million, a 68.06% decrease from a year earlier, with the FY2025 full-year figure at $7.6 million, up 349.79% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $3.2 million, down from $7.6 million in the prior quarter.
• Over the last five years, Total Current Liabilities for ASBP reached as high as $13.9 million in Q3 2025 and fell as low as $51756.0 in Q1 2022.
• Historically, Total Current Liabilities has averaged $3.6 million across 5 years, with a median of $1.0 million in 2023.
• Across the five-year window, Total Current Liabilities jumped 2094.53% in 2024 and tumbled 68.06% in 2026, its largest moves.
• Year by year, Total Current Liabilities stood at $303323.0 in 2022, then jumped by 32.97% to $403328.0 in 2023, then soared by 318.54% to $1.7 million in 2024, then jumped by 349.79% to $7.6 million in 2025, then sank by 58.48% to $3.2 million in 2026.
• Per Business Quant data, the three most recent Total Current Liabilities figures were $3.2 million in Q1 2026, $7.6 million in Q4 2025, and $13.9 million in Q3 2025.